In another ovarian cancer study, immunohistochemical staining showed that only 15.1% (8/53) of tissues show CDX2 expression and CDX2 was found to contribute to chemoresistance via the promotion of MDR1 (multidrug resistance 1) gene expression [42]. This evidence concerns the gene CDX2 and ovarian carcinoma.